EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review

Ioanna A Paschou iD, Evangelia Sali, Stavroula A Paschou, Theodora Psaltopoulou, Electra Nicolaidou iD, Alexander J Stratigos

Journal of the European Academy of Dermatology and Venereology · 2025-12 · 39 (12) · 2047-2055

DOI: 10.1111/jdv.20694 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 29.04.2025. Verfasst von Ioanna A Paschou und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens,…. Hauptthemen laut MEDLINE: Psoriasis, Glucagon-Like Peptide-1 Receptor Agonists, Hidradenitis Suppurativa. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Empirikeion Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP‐1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction. It has also been established that GLP‐1RA have immunological and anti‐inflammatory effects. The aim of this article was to comprehensively review the literature and to collect, analyse and quantitatively resynthesize evidence on the possible effects of GLP‐1RA on inflammatory skin diseases. Through body weight reduction and subsequent systemic inflammation reduction, but mainly through their direct interaction with signalling pathways of inflammation and immune cells, GLP‐1RA can improve psoriasis and hidradenitis suppurativa (HS). Clinical data of the positive effects of GLP‐1RA in patients with psoriasis and HS are presented. Moreover, the immune cells and inflammatory pathways affected by GLP‐1RA are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisGlucagon-Like Peptide-1 Receptor AgonistsHidradenitis SuppurativaHumans

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • 1st Department of Dermatology and Venereology, "Andreas Sygros" Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Ioanna A Paschou, Electra Nicolaidou

Förderung

  • Empirikeion Foundation

Zitieren

APA

Paschou, I. A., Sali, E., Paschou, S. A., Psaltopoulou, T., Nicolaidou, E., & Stratigos, A. J. (2025). The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review. Journal of the European Academy of Dermatology and Venereology, 39(12), 2047-2055. https://doi.org/10.1111/jdv.20694

Vancouver

Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ. The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review. Journal of the European Academy of Dermatology and Venereology. 2025;39(12):2047-2055. doi:10.1111/jdv.20694

BibTeX
@article{Paschou2025,
  author = {Paschou, Ioanna A and Sali, Evangelia and Paschou, Stavroula A and Psaltopoulou, Theodora and Nicolaidou, Electra and Stratigos, Alexander J},
  title = {The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {12},
  pages = {2047--2055},
  doi = {10.1111/jdv.20694}
}
Kostenlos starten →